This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.
A Phase III clinical trial called SURMOUNT-ADOLESCENTS tested whether a once-weekly dose of tirzepatide combined with healthy lifestyle counseling is safe and effective for helping teenagers lose weight and improve their health.
A total of 160 teenagers across 31 medical centers in six countries who had obesity or were overweight with at least one related health complication such as high blood pressure or prediabetes received either a once-weekly shot of tirzepatide or a placebo for 72 weeks.
After the trial period, participants taking tirzepatide saw their average BMI fall by 18.5%, while the placebo group recorded a 0.5% increase. This is not to be confused with percentage weight loss, as BMI is a tool that uses a person's height and weight to estimate body fat and gauge potential health risks.
This drop also translated into lower obesity rates, with around 54% of participants on tirzepatide falling below the obesity threshold for their age and sex, compared with just 7% in the placebo group.
Source link







